Call for papers accelerates cancer information transfer - ecancermedicalscience

ecancermedicalscience aims to improve communications between sub-specialised cancer scientists and clinicians by working interactively and faster - offering authors a rapid peer review process. Submit your paper and you'll hear if it will be published within three weeks.

ecancermedicalscience (ISSN 1754-6605) is an independent online journal, publishing research articles after full peer review. All articles are published online immediately upon acceptance. The journal is published by Cancer Intelligence Ltd, Westpoint, 78 Queens Road, Clifton, Bristol, BS8 1QU.

ecancermedicalscience, founded by the European Institute of oncology, is proud to acknowledge The European CanCer Organisation as its educational and Scientific partner.

Criteria for publication
Publication of research articles by ecancermedicalscience is dependent primarily on their validity and coherence, as judged by a peer reviewer. The reviewer is asked how remarkable they consider the article to be. ecancermedicalscience is interested in publishing; innovative studies testing new hypotheses; policy research papers that challenge conventional thinking and case studies that address new and interesting ways of working.

Speed of publication
ecancermedicalscience offers fast publication whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed electronically. A web version, and accompanying PDF, will be published within a few days of acceptance.

For further information, please visit:
http://www.ecancermedicalscience.com

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...